Corient Private Wealth LLC Purchases 7,166 Shares of Charles River Laboratories International, Inc. $CRL

Corient Private Wealth LLC lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 68.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,628 shares of the medical research company’s stock after acquiring an additional 7,166 shares during the quarter. Corient Private Wealth LLC’s holdings in Charles River Laboratories International were worth $3,516,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Tema Etfs LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Charles River Laboratories International during the fourth quarter worth $42,000. Sfam LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $43,000. Activest Wealth Management increased its stake in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at about $46,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $215.68 on Friday. The firm has a market cap of $10.39 billion, a price-to-earnings ratio of -57.36, a PEG ratio of 2.46 and a beta of 1.46. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $228.88. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The stock has a 50-day moving average price of $176.98 and a 200 day moving average price of $183.36.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same period in the prior year, the company posted $2.34 EPS. The company’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts expect that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CRL shares. Barclays upped their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 target price for the company. Mizuho set a $192.00 target price on shares of Charles River Laboratories International in a research report on Friday, May 8th. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and increased their price target for the company from $167.00 to $219.00 in a research note on Friday, May 29th. Finally, Robert W. Baird set a $213.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.